Interventional Strategies in Cancer-induced Cardiovascular Disease

Pushparaji, Bala; Donisan, Teodora; Balanescu, Dinu Valentin; Palaskas, Nicolas; Kim, Peter; Lopez‐Mattei, Juan; Çilingiroğlu, Mehmet; Hassan, Saamir; Boudoulas, Konstantinos Dean; Marmagkiolis, Konstantinos; Hajjar, Ludhmila Abrahão; Iliescu, Cezar

doi:10.1007/s11912-021-01113-y

Cited by 3 publications

(3 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However in March 2022, he became progressively short of breath. Echocardiography demonstrated a dilated cardiomyopathy with an ejection fraction of 30%–35%, but was not in keeping with carcinoid cardiomyopathy, 10 and coronary angiography excluded an ischemic cause. He remained frail, and following a vacation, suffered a cardiorespiratory arrest and died in March 2023.…”

Section: Case Reportmentioning

confidence: 93%

Dosing lutetium Lu 177‐dotatate for a hemodialysis patient

Taylor,

Meades,

Quigley

et al. 2024

Hemodialysis International

View full text Add to dashboard Cite

Lu177‐dotatate (Lutathera™) is a radioactive drug approved for the treatment of adults with gastro‐entero‐pancreatic neuroendocrine tumors and is predominantly renally excreted. Currently all patients receive 7400 MBq (200 mCi), and there are no guidelines for treating hemodialysis patients. We measured radioactivity prior to and post administration of two cycles of Lu177‐dotatate in a hemodialysis patient, and radiation exposure to staff. We reduced the standard 7400 MBq by 33% for the first cycle and patient radioactivity fell by 40% following postdilution hemodiafiltration started 6 h post dosing, and by 45% for the second cycle and radioactivity fell by 47% with postdilution hemodiafiltration started 5 h post administration. By reducing the initial administered radioactivity, coupled with early dialysis, and choosing postdilution hemodiafiltration we were able to achieve radioactivity retention curves similar to those from patients with normal renal function receiving the standard administration of 7400 MBq.

show abstract

Section: Case Reportmentioning

confidence: 93%

Dosing lutetium Lu 177‐dotatate for a hemodialysis patient

Taylor,

Meades,

Quigley

et al. 2024

Hemodialysis International

View full text Add to dashboard Cite

show abstract

“…However, the incidence and mortality due to complications induced by anticancer treatments have increased each year. Cardiovascular disease is the most common adverse reaction of antitumor therapy [1,2]. Doxorubicin (Dox) is an antitumor drug that is widely used against a variety of malignant tumors, including lymphoma, leukemia, and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation

Zhang

Tou

Yuliang

et al. 2023

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Patients undergoing doxorubicin (Dox) chemotherapy often develop new-onset atrial fibrillation and heart failure. Recent studies indicate that the TLR4/MyD88/NLRP3 pyroptosis signaling pathway plays a key role in the occurrence and development of cancer, heart failure, and atherosclerosis. However, few studies investigated the role of oxidative stress and pyroptosis in doxorubicin-induced heart failure and new-onset atrial fibrillation. In this study, we recruited 84 healthy subjects, 112 patients undergoing Dox chemotherapy showing heart failure (HF), and 62 patients undergoing Dox treatment who manifested atrial fibrillation (AF). The mRNA and protein levels of TLR4 expression, several downstream pyroptosis-associated proteins (cleaved caspase-1, NLRP3, GSDMD-N, and HMGB-1), serum inflammatory factors, and oxidative stress were detected at the beginning of chemotherapy and after 3 months of Dox chemotherapy. Oxidative stress and downstream pyroptosis-associated proteins tended to increase in the Dox-baseline group to the Dox-HF group. However, virtually no change in the expression of either oxidative stress or pyroptosis-associated proteins was detected in patients after three months of Dox chemotherapy compared with those at baseline. This study suggests that the prolonged oxidative stress and high levels of pyroptosis-associated proteins contribute to cardiac systolic dysfunction, suggesting TLR4 as a novel biomarker and a potential treatment target for doxorubicin-induced heart failure.

show abstract

Methanolic Extract of Morchella esculenta (Ascomycota) Prevents Chemotherapy-Related Cardiotoxicity in Tumor-Bearing Mice

Das,

Mathew,

Janardhanan

2025

Int J Med Mushrooms

View full text Add to dashboard Cite

The quest for bioactives that confer protection against chemotherapy induced cardio toxicity is a front-line area of cardio oncology research. Species of genus Morchella have been used in traditional medicine to treat asthma, wound healing, cough, cold, indigestion, excessive phlegm and breathlessness. M. esculenta, commonly known as guchhi in India is a highly prized culinary morel mushroom. Recent studies carried out in our laboratory have demonstrated significant cardioprotective effect of M. esculenta against doxorubicin (DOX)-induced cardiotoxicity. Since bioactive extracts of morel mushrooms were found to possess profound antioxidant activity, the possible interference of these extracts with antineoplastic activity of chemotherapy drugs is often surmised. The current study was undertaken to evaluate the effect of two anticancer drugs, DOX and cyclophosphamide (CP) on solid tumor-bearing mice treated with bioactive extract of M. esculenta. Solid tumor was induced by subcutaneous injection of Dalton's lymphoma ascites (DLA) cells on the right hind limbs of Swiss albino mice. Animals were administered with various concentrations of methanol extract (ME) of M. esculenta following tumor induction. Tumor growth (volume and mass) was measured for four weeks after tumor induction. Cardioprotective effect of methanolic extract was assessed by determining cardiac injury markers levels in serum, antioxidant status in myocardium and histopathology of heart tissue. The results showed significant cardioprotective effect of ME of M. esculenta on tumor-bearing mice. The findings also suggest that ME of M. esculenta did not delimit the therapeutic effect of DOX and CP despite its profound antioxidant activity.

show abstract

Interventional Strategies in Cancer-induced Cardiovascular Disease

Cited by 3 publications

References 91 publications

Dosing lutetium Lu 177‐dotatate for a hemodialysis patient

Dosing lutetium Lu 177‐dotatate for a hemodialysis patient

Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation

Methanolic Extract of Morchella esculenta (Ascomycota) Prevents Chemotherapy-Related Cardiotoxicity in Tumor-Bearing Mice

Contact Info

Product

Resources

About